Nektar Therapeutics (NKTR)

Nektar Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-276.06	-368.2	-523.84	-444.44	-440.67
Depreciation & Amortization	7.82	13.03	14.15	14.18	13.16
Share-Based Compensation	33.39	57.32	94.67	94.26	99.8
Other Operating Activities	42.25	-6.16	2.36	22.71	-0.97
Operating Cash Flow	-192.61	-304.01	-412.66	-313.29	-328.68
Capital Expenditures	0.38	7.52	-14.99	-7.26	-26.29
Change in Investments	139.18	358.32	217.77	503.47	233.17
Investing Cash Flow	139.56	365.84	202.78	496.21	206.89
Share Issuance / Repurchase	0.03	0.76	33.24	23.4	23.36
Debt Issued / Paid	0	0	0	-250	0
Other Financing Activities	-	0.75	3	146.25	-
Financing Cash Flow	0.03	1.51	36.24	-80.35	23.36
Exchange Rate Effect	0.06	-0.33	-0.09	0.02	-0.1
Net Cash Flow	-52.95	63.01	-173.74	102.59	-98.54
Free Cash Flow	-192.23	-296.49	-427.65	-320.55	-354.97
Free Cash Flow Margin	-213.30%	-322.08%	-419.65%	-209.62%	-309.70%
Free Cash Flow Per Share	-1.01	-1.58	-2.33	-1.79	-2.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).